Table 3.
Days of hospitalization, mean ± SD | 49 ± 45 |
Range, d | 8–357 |
BK virus | 16 (10.3) |
CMV | 67 (42.9) |
Infection | 134 (83.2) |
Severe infection | 96 (60) |
Bacterial infection | 112 (69.6) |
Recurrent urinary tract infections | 29 (18.7) |
Pneumonitis | 31 (19.6) |
Viral infection | 21 (13.3) |
Fungal infection | 16 (10.1) |
Parasitic infection | 6 (3.9) |
Cardiovascular event | 73 (45.1) |
ADHF | 23 (13.5) |
Recurrent ADHF | 10 (5.8) |
Deep vein thrombosis/Pulmonary embolism | 22 (12.9) |
Arrhythmia | 19 (11.1) |
Myocardial ischemia | 10 (5.8) |
Cerebrovascular event | 3 (1.8) |
Urologic complication | 94 (56.9) |
Lymphocele | 19 (11.1) |
Hematoma | 19 (11.1) |
Acute urinary retention | 18 (10.5) |
Ureteral stenosis | 18 (10.5) |
Transplant renal artery stenosis | 9 (5.3) |
Skin tumor | 11 (7.1) |
Solid tumor | 5 (3.2) |
Hemopathy/Lymphoma | 6 (3.8) |
TCMR | 27 (17.1) |
Time to TCMR, d (mean ± SD) | 124 ± 104 |
ABMR | 8 (5.2) |
Time to ABMR, d (mean ± SD) | 171 ± 128 |
Death | 17 (9.9) |
Cause of death | |
Infection | 10 (58.8) |
Cardiovascular disease | 5 (29.4) |
Graft loss | 40 (23.4) |
Death-censored graft loss | 29 (16.9) |
Cause of graft loss | |
Death | 11 (28.2) |
Rejection | 10 (25.6) |
Vascular | 7 (17.9) |
ABMR, antibody-mediated rejection; ADHF, acute decompensated heart failure; CMV, cytomegalovirus; TCMR, T-cell mediated rejection.